Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1979 1
1996 1
1998 2
1999 4
2000 5
2001 2
2002 2
2003 4
2004 4
2005 1
2006 3
2007 1
2008 5
2009 3
2010 3
2011 4
2012 10
2013 3
2014 6
2015 12
2016 8
2017 6
2018 5
2019 11
2020 12
2021 17
2022 8
2023 8
2024 15
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for zurita a[au]
Your search for Yurrita A[au] retrieved no results
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Tang C, et al. Among authors: zurita aj. JAMA Oncol. 2023 Jun 1;9(6):825-834. doi: 10.1001/jamaoncol.2023.0161. JAMA Oncol. 2023. PMID: 37022702 Free PMC article. Clinical Trial.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Corn PG, et al. Among authors: zurita a. Lancet Oncol. 2019 Oct;20(10):1432-1443. doi: 10.1016/S1470-2045(19)30408-5. Epub 2019 Sep 9. Lancet Oncol. 2019. PMID: 31515154 Free PMC article. Clinical Trial.
Archival single-cell genomics reveals persistent subclones during DCIS progression.
Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL; Grand Challenge PRECISION Consortium; Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Wang K, et al. Among authors: zurita aj. Cell. 2023 Aug 31;186(18):3968-3982.e15. doi: 10.1016/j.cell.2023.07.024. Epub 2023 Aug 15. Cell. 2023. PMID: 37586362 Free article.
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Aparicio AM, et al. Among authors: zurita aj. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649003 Free PMC article.
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Karam JA, et al. Among authors: zurita aj. Nat Commun. 2023 May 10;14(1):2684. doi: 10.1038/s41467-023-38342-7. Nat Commun. 2023. PMID: 37164948 Free PMC article. Clinical Trial.
Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics.
Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, Pienta KJ, Zurita AJ, Gross ME, Shishido SN, Hicks J, Velasco CR, Kuhn P. Welter L, et al. Among authors: zurita aj. Cancers (Basel). 2023 Aug 3;15(15):3949. doi: 10.3390/cancers15153949. Cancers (Basel). 2023. PMID: 37568766 Free PMC article.
18F-Fluciclovine Uptake in a Ureterocele.
Bitar R, Szklaruk J, Martiniova L, Zurita AJ, Chery LJ, Ravizzini G. Bitar R, et al. Among authors: zurita aj. Clin Nucl Med. 2021 Jan;46(1):e3-e5. doi: 10.1097/RLU.0000000000003272. Clin Nucl Med. 2021. PMID: 32956112
Body composition as a determinant of the therapeutic index with androgen signaling inhibition.
Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Hahn AW, et al. Among authors: zurita aj. Prostate Cancer Prostatic Dis. 2024 Jul 17. doi: 10.1038/s41391-024-00870-8. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39019979
Fleas and flea-borne diseases of North Africa.
Hamzaoui BE, Zurita A, Cutillas C, Parola P. Hamzaoui BE, et al. Among authors: zurita a. Acta Trop. 2020 Nov;211:105627. doi: 10.1016/j.actatropica.2020.105627. Epub 2020 Jul 9. Acta Trop. 2020. PMID: 32652054 Review.
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Alhalabi O, et al. Among authors: zurita a. NPJ Precis Oncol. 2023 Apr 18;7(1):37. doi: 10.1038/s41698-023-00369-w. NPJ Precis Oncol. 2023. PMID: 37072571 Free PMC article. Review.
154 results